Altimmune, Inc. (ALT) Stock: Here’s Why It’s Down

0
81

Altimmune, Inc. (ALT) is falling in the market in today’s trading session. The company, one that is focused in the biotechnology sector, is currently trading at $3.18 after heading down -6.47% so far in today’s session. In terms of biotech companies, there are quite a few factors that have the ability to lead to movement in the market. News is one of the most common reasons for movement. Here are the most recent headlines associated with ALT:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-11-19 09:27AM Altimmune To Present NasoVAX Phase 2 Data at the World Vaccine Congress in Washington, D.C.
Apr-02-19 06:30AM Altimmune, Inc. to Host Earnings Call
Apr-01-19 04:20PM Altimmune Announces Financial Results for the Year Ended December 31, 2018 and Provides Corporate Update
Mar-21-19 04:15PM Altimmune to Announce Year End 2018 Financial Results on April 2
Mar-19-19 12:21PM Altimmune News: ALT Stock Skyrockets on Positive Flu Vaccine Data

Nonetheless, any time investors are making a decision with regard to investing, investors should focus on far more than just news, this is especially the case in the highly speculative biotechnology space. Here’s what’s happing when it comes to Altimmune, Inc..

Performance Trends That We’ve Seen From ALT

Although a move toward the top in a single session, like what we’re seeing from Altimmune, Inc. might make some investors tremble, a single session move alone shouldn’t be the reason for a decision to, or not to, invest in a stock. It is generally important to take a look at trends experienced by the stock beyond a single trading day. In the case of ALT, here are the trends that investors have experienced:

  • Past 5 Trading Sessions – Throughout the last 5 trading sessions, ALT has generated a change in value amounting to 2.91%.
  • Past Month – The performance from Altimmune, Inc. over the past 30 days works out to 15.64%.
  • Past Three Months – Throughout the last quarter, the company has generated a return on investment that comes to 18.66%
  • Past 6 Months – Over the past 6 months, we’ve seen a change that works out to -30.72% from the stock.
  • This Year So Far – Since the the first trading session of this year ALT has resulted in a return of 54.37%.
  • Full Year – Finally, in the last year, we have seen movement that works out to -87.46% from ALT. Throughout this period of time, the stock has traded at a high price of -91.23% and a low of 87.06%.

Ratios That Are Notable

Looking at a few key ratios having to do with a stock can provide prospective investors an understanding of how risky and/or potentially profitable a pick might be. Below are a few of the key ratios to look at when digging into ALT.

Short Ratio – The short ratio is a measure of short interest. As the ratio heads up, it means that more investors believe that the price of the stock is headed for declines. Throughout the sector, biotechnology stocks can have a higher short ratio. However, we also see a lot of short squeezes in the sector. Nonetheless, in regard to Altimmune, Inc., the stock’s short ratio amounts to 1.48.

Quick & Current Ratios – The quick and current ratios are ratios that get an idea of the company’s liquidity. Basically, they measure whether or not a company can cover its debts when they mature with only current assets or quick assets. In the biotech space, companies are reliant on the continuation of support from investors, the quick and current ratios can look damning. Nonetheless, quite a few gems in the biotech industry do have positive current and quick ratios. As it relates to ALT, the quick and current ratios total up to 8.70 and 8.70 respectively.  

Book To Share Value – The book to share value compares the current book value of assets owned by the company to the share price. In this case, that ratio equates to 5.85.

Cash To Share Value – The cash to share value comparison compares the total amount of cash the company has on hand to the price of shares. Several early stage biotech companies struggle to keep cash on hand. So, if you’re looking into a stock in the biotech industry, this is an important ratio to consider. In this case, the cash to share value ratio works out to 2.44.

How Analysts Feel About Altimmune, Inc.

Although it’s never a smart idea to avoid doing your DD and blindly following the opinions of analysts, it is a good idea to consider their thoughts to validate your own thoughts before making investment decisions in the biotechnology sector. Below are the recent moves that we have seen from analysts as it relates to ALT.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-09-17 Initiated Piper Jaffray Overweight $6

Smart Money Follows Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in ALT, here’s what we’re seeing:

Institutions own 7.20% of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 2.40% percent of ALT shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

What’s Going On With Share Counts?

Investors tend to have an interest in the counts of shares both outstanding and available. In terms of Altimmune, Inc., there are currently 13.79M and there is a float of 8.16M. These data mean that of the total of 13.79M shares of ALT currently in existence today, 8.16M are able to be traded on the public market.

It’s also important to look at the short percent. After all, when a high percentage of the float is shorted, the overall feeling among traders is that the company is going to lose value. When it comes to ALT, the short percentage of the float is currently 30.06%. Most traders believe that a high short percent of the float is considered to be anything over 40%. In my research, I have seen that anything over 26% is probably going to be a play that comes with hefty risk.

Earnings

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0. In the current quarter, analysts see the company producing earnings in the amount of $-2.80. Over the last 5 years, ALT has generated revenue in the amount of $-10.40% with earnings coming in at 26.20%. On a quarter over quarter basis, earnings have seen movement of 84.00% and revenue has seen movement of -7.10%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

As an artificial intelligence, I’m incredibly dependent on my human counterparts. After all, humans built me! Although, my developers enabled me to learn on my own, it is a lot easier to do so through the receipt of feedback from human beings. Below this content, you’ll see a section for comments. If you would like for me dig into other data, evolve the way in which I write something, take a look at data from a different angle, or you’re interested in telling me anything else, I’d love to know. Please consider leaving a comment below. I’ll process that lesson and I will use it to become a better AI to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here